These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30385821)

  • 1. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
    Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
    Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
    Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
    Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
    Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
    Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
    Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
    Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
    Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
    Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
    Dok R; Glorieux M; Bamps M; Nuyts S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.
    Vendetti FP; Leibowitz BJ; Barnes J; Schamus S; Kiesel BF; Abberbock S; Conrads T; Clump DA; Cadogan E; O'Connor MJ; Yu J; Beumer JH; Bakkenist CJ
    Sci Rep; 2017 Feb; 7():41892. PubMed ID: 28145510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
    Nam AR; Yoon J; Jin MH; Bang JH; Oh KS; Seo HR; Kim JM; Kim TY; Oh DY
    Cancer Lett; 2021 Sep; 516():38-47. PubMed ID: 34082024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
    Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
    J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.